About
VVT Medical specializes in the research, development, manufacturing and commercialization of minimally invasive, non-thermal non-tumescent- NT-NT solutions for the treatment of varicose veins.
VVT Medical’s advanced, proprietary solutions combine best practices in vein treatment with a powerful, patented delivery system to provide a simpler, more effective approach to treatment. Its flagship ScleroSafe platform enables physicians to perform quick, office-based procedures without the need for tumescent anesthesia or costly capital equipment. VVT Medical’s solutions can be performed in a range of outpatient settings including vein clinics, day care clinics, angio suites, catheterization laboratories and hospitals.
ScleroSafe with V-Block is especially designed to simply, safely and effectively treat severely dilated and challenging Great Saphenous Vein (GSV) conditions, including GSV valve incompetence and Reflux.
Funding history · 1 round · $1.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did VVT Medical begin trading on the TSX Venture Exchange?
- VVT Medical Inc. announced the commencement of trading on the TSX Venture Exchange in July 2025.
- What was the nature of VVT Medical's last funding round and who was the lead investor?
- VVT Medical's last funding round was a PIPE (Private Investment in Public Equity) in July 2025, with I3 Capital Group as the lead investor. For full financing history, please refer to startupim.
- What significant distribution agreement did VVT Med sign in November 2025?
- In November 2025, VVT Med signed a $3.7 million distribution agreement in India.
- What clinical data was published for VVT Med's ScleroSafe® in April 2026?
- In April 2026, VVT Med announced positive clinical data for ScleroSafe® was published in the peer-reviewed Indian Journal of Vascular and Endovascular Surgery.
- What was the outcome of VVT Med's application for a Management Cease Trade Order in May 2026?
- In May 2026, VVT Med announced the receipt of a Management Cease Trade Order.
- What was the value of the first tranche of VVT Med's private placement closed in April 2026?
- In April 2026, VVT Med closed a $1,065,664 first tranche of a private placement of units.
- What significant European distribution agreement did VVT Med sign in April 2026?
- In April 2026, VVT Med signed its largest European distribution agreement to date, with the distributor also joining as an investor.
- When did VVT Medical submit its FDA 510(k) for the ScleroSafe™ System?
- VVT Medical announced the FDA 510(k) submission for its ScleroSafe™ System in April 2023.